LQDA

Liquidia Technologies Inc

LQDA, USA

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

https://www.liquidia.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
LQDA
stock
LQDA

Arquitos Capital Management’s Updates on Liquidia Corporation (LQDA) Insider Monkey

Read more →
LQDA
stock
LQDA

HighVista Strategies LLC Sells 82,869 Shares of Liquidia Corporation $LQDA MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$44

Analyst Picks

Strong Buy

6

Buy

3

Hold

0

Sell

0

Strong Sell

1

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

130.72

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-16.02 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-1.28 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-19.66 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

11.52

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 63.48% of the total shares of Liquidia Technologies Inc

1.

Caligan Partners LP

(9.4305%)

since

2025/06/30

2.

BlackRock Inc

(5.6825%)

since

2025/06/30

3.

Farallon Capital Management, L.L.C.

(4.9236%)

since

2025/06/30

4.

Vanguard Group Inc

(4.1741%)

since

2025/06/30

5.

Findell Capital Management LLC

(3.4847%)

since

2025/06/30

6.

Opaleye Management Inc

(2.8748%)

since

2025/06/30

7.

Goldman Sachs Group Inc

(2.8075%)

since

2025/06/30

8.

Vanguard Total Stock Mkt Idx Inv

(2.3352%)

since

2025/07/31

9.

State Street Corp

(2.1265%)

since

2025/06/30

10.

HHG PLC

(1.8956%)

since

2025/06/30

11.

Deerfield Management Co

(1.878%)

since

2025/06/30

12.

iShares Russell 2000 ETF

(1.8045%)

since

2025/08/31

13.

Geode Capital Management, LLC

(1.6329%)

since

2025/06/30

14.

Whitefort Capital Management, LP.

(1.5467%)

since

2025/06/30

15.

Tyro Capital Management LLC

(1.4425%)

since

2025/06/30

16.

Jupiter Merian Glb Eq AbsRet I USD Acc

(1.4235%)

since

2025/06/30

17.

TANG CAPITAL MANAGEMENT LLC

(1.3285%)

since

2025/06/30

18.

CenterBook Partners LP

(1.2822%)

since

2025/06/30

19.

Patient Square Capital

(1.1848%)

since

2025/06/30

20.

Susquehanna International Group, LLP

(1.1611%)

since

2025/06/30

21.

FMR Inc

(1.0622%)

since

2025/06/30

22.

Two Sigma Investments LLC

(0.8677%)

since

2025/06/30

23.

Shay Capital LLC

(0.8198%)

since

2025/06/30

24.

Fidelity Small Cap Index

(0.7477%)

since

2025/06/30

25.

Fidelity Small Cap Growth

(0.7033%)

since

2025/06/30

26.

iShares Russell 2000 Growth ETF

(0.6506%)

since

2025/08/31

27.

Vanguard Institutional Extnd Mkt Idx Tr

(0.5965%)

since

2025/07/31

28.

Oberweis Micro-Cap Growth

(0.3731%)

since

2025/06/30

29.

Oberweis Micro-Cap

(0.3731%)

since

2025/06/30

30.

Vanguard Russell 2000 ETF

(0.3554%)

since

2025/07/31

32.

Fidelity Small Cap Growth K6

(0.3401%)

since

2025/06/30

33.

Fidelity Extended Market Index

(0.3015%)

since

2025/07/31

34.

State St Russell Sm Cap® Indx SL Cl I

(0.2631%)

since

2025/08/31

35.

Schwab US Small-Cap ETFâ„¢

(0.2626%)

since

2025/08/30

36.

Vanguard Health Care ETF

(0.2297%)

since

2025/07/31

37.

SPDR® S&P Pharmaceuticals ETF

(0.2184%)

since

2025/08/31

38.

Schwab Small Cap Index

(0.1907%)

since

2025/07/31

39.

NT R2000 Index Fund - NL

(0.1805%)

since

2025/06/30

40.

iShares Micro-Cap ETF

(0.1689%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.1867

Latest Release

Date

2025-09-30

EPS Actual

-0.04

EPS Estimate

-0.41

EPS Difference

0.37

Surprise Percent

90.2439%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(3)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(1.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.